Trend

QS Research · Michael Burry's Scion Capital analyst template · 2006

Z Squared Inc. (ZSQR)

As of 2026-11-21 · 11/15 boxes filled from SEC filings and market data

Report price $1.74 (close 2026-11-20)

Conclusion: PASS

Conviction low · base case none · downside -15% · upside 0%

The market pays 31.21x TTM revenue of $2.9M for a business with a -19.8% TTM gross margin and -$26.8M TTM EBIT, and the only positive multiple is 0.69x price/book on $132.5M of equity being consumed at a -19.4% return on common equity. The call is PASS on low conviction: there is no dated catalyst in the sources that would re-rate the business, and the pending merger that would spin out the biotech assets is the only event that could change the story. The downside case is -15.0% to $1.47, on 0.0% book value at a compressed P/B of 0.59x (today 0.69x). There is no base case: no comparable peer multiple sets one, and a base at today's multiple is today's price by construction. The upside case is 0.0% to $1.74, the analyst's own upside (no earnings change was given to price it).

Key numbers

  • Share price: $1.74
  • Market cap: $92.0M
  • Latest financial period: TTM to Jun 30, 2026
  • Revenue (TTM): $2.9M
  • Price / book: 0.69x
  • Earnings-quality flags (TTM): Mark-to-market on the company's own stock (warrants) $191,625 (1% of net income)

The 15 boxes

  1. ✓ 1. Long-form business notes

    ZSQR is a shell that has been rebuilt twice: it filed as a $75.0M-IPO blank check company (Bull Horn Holdings Corp., FY2020), became Coeptis Therapeutics Holdings, Inc. on 2022-10-28 after merging in Coeptis Therapeutics, Inc., and filed this FY2025 10-K as a six-employee holding company with a preclinical cell-therapy division and, since 2024-12-19, an AI marketing-services division; it now files as Z Squared Inc. (renamed 2026-04-28). Revenue is only now reappearing, from the acquired marketing platform: $1.4M in FY2025 and $2.9M in the TTM to 2026-06-30, but gross profit went from +$1.2M in FY2025 to -$583,527 TTM and operating income was -$13.0M in FY2025 and -$26.8M TTM. Operating cash flow was -$8.6M FY2025 and -$8.8M TTM, and the 10-K cites substantial doubt about going concern. The intended end-state is the April 25, 2025 merger with Z Squared, Inc. (Wyoming), in which Coeptis spins out the biotech operations and Z Squared survives as a wholly owned subsidiary, expected to close in Q2 2026.

  2. ✓ 2. Competitive advantage

    No durable advantage is visible in these sources. Revenue was $75,000 in FY2021, zero in FY2022, FY2023 and FY2024, $1.4M in FY2025 and $2.9M on the TTM to 2026-06-30, and gross profit of $1.2M in FY2025 turned to -$583,527 on that TTM basis, so there is no pricing power or scale benefit in the numbers. Every fiscal year on record shows a double-digit-million operating loss (FY2024 -$10.1M, FY2025 -$13.0M, TTM -$26.8M), the 10-K reports a $109,953,728 accumulated deficit at 2025-12-31 and a going-concern explanatory paragraph, and the company funds itself by issuing equity, not from operations. The 10-K competes against unnamed 'many companies, universities, and research organizations' with greater financial, clinical and regulatory resources, and it frames patent and licensing protection as risks rather than as an established moat.

  3. ✓ 3. 10-Q takeaways

    The latest 10-Q in the provided sources covers the quarter ended 2026-06-30 and was filed 2026-08-13, with MD&A in Item 2 and a risk-factor update in Item 1A. The computed 10-K risk-factor diff flags two paragraphs as new or rewritten past recognition, including FDA/clinical-test and data-interpretation risk. The supplied excerpts do not include numeric sales, margin, inventory, cash, buyback or guidance detail.

  4. ✓ 4. Corporate governance

    Filled; members read this box.

  5. ✓ 5. Overview of the prior 3 years of 8-K filings

    Filled; members read this box.

  6. ✓ 6. Other significant filings

    Filled; members read this box.

  7. ○ 7. Chronology of significant news and events
  8. ✓ 8. Comparables valuation interpretation

    Filled; members read this box.

  9. ✓ 9. Insider trading interpretation

    Filled; members read this box.

  10. ○ 10. Earnings-call notes
  11. ○ 11. Impression of the shareholder letter
  12. ○ 12. Scuttlebutt overview
  13. ✓ 13. Valuation and risk/reward summary

    Filled; members read this box.

  14. ✓ 14. Current price suppression and potential catalysts

    Filled; members read this box.

  15. ✓ 15. Conclusions

    The call above.

Sign in with a QuantSignals Premium or Gold plan to read every box: each point linked to the SEC filing it came from, the bull and bear case, and the comparables. QS Research powers the signals behind FST, our autonomous trading agent.

Put these signals to work

The Scion template's preview is free. Paid members read every box of every report. FST, the QuantSignals trading agent, uses QS Research as its brain.

Join freeMeet FSTSee plans